NASDAQ · DMAC
DiaMedica Therapeutics Inc.
Healthcare · Biotechnology
$8.13▼ 2.23% ($0.19)today
As of 12:17 PM ET
Market cap
$438.32M
P/E
-11.30
EPS (TTM)
-$0.70
Next earnings
Nov 11, 2026
Valuation
Revenue & margin DCF
A cash-flow estimate wouldn't be reliable here
Need reported operating working-capital balances or comparable changes in working capital to forecast reinvestment; an unknown requirement cannot be treated as zero.
Fewer than two comparable annual revenue periods are available, so growth is taken from the latest quarterly year-over-year figure without the annual cross-check.
Data notes
Fewer than two comparable annual revenue periods are available, so growth is taken from the latest quarterly year-over-year figure without the annual cross-check.
- 10-yr revenue CAGR
- —
- Ending operating margin
- —
- Discount rate
- —
USD · Price used $8.13 · Price Sep 29, 4:17 PM UTC
What each scenario assumes. Click a column to start from it.
Price vs Fundamentals
Why The Stock Is Moving
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
What changed
The stock rose 17.73% over the last year. Free cash flow declined 23.03% over the trailing twelve months.
What the market seems to be pricing
The stock has moved higher against modestly weakening underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
A decisive shift in revenue or cash flow over the next period would be the clearest signal to resolve the ambiguity.
Return analysis
Company profile
DiaMedica Therapeutics Inc. operates as a clinical-stage biopharmaceutical entity dedicated to advancing therapeutic solutions for neurological and renal disorders.
Market multiples
Stock splits
Every 20 shares became 1
Profitability & growth
Analyst consensus
6
Buy
0
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Nov 11, 2026
Q3 FY26 · EPS est -$0.20 · Revenue est $13.5M
View
Institutional Sentiment
DiaMedica Therapeutics Inc. · DMAC
From Form 13F filings (managers with $100M+). Filings land up to 45 days after quarter end — read this as positioning context, not live fund flow.